A case of pseudoaldosteronism, accompanied with hypocalcemia and exaggerated ACTH response.
Glycyrrhizic acid (GA) inhibits the activity of 11beta-hydroxysteroid dehydrogenase type 2 in the kidney, with the resulting increase in intrarenal cortisol concentration leading to hypertension and suppression of the renin-aldosterone system. In this paper we describe an interesting case of pseudoaldosteronism, associated with hypocalcemia and an exaggerated ACTH response. A 72-year-old woman was referred to our department for further evaluation of hypokalemia and hypocalcemia. The patient had been taking GA (150 mg/day) for the previous year for treatment of liver damage. Plasma renin activity and aldosterone concentration were both within lower normal limits. Urinary excretion of potassium and calcium was within the upper limit of the normal range and increased with administration of supplements. Plasma ACTH levels increased markedly in response to an intravenous injection of CRH. Cessation of GA and the potassium and calcium supplements on admission, led to a gradual normalization of serum potassium and calcium levels and blood pressure. The hypocalcaemia in our patient was related to decreased tubular reabsorption of calcium as a consequence of renal corticoid excess. It is possible that an increase in the number of CRH receptors in the pituitary following GA treatment caused the exaggerated ACTH response in association with pseudoaldosteronism. The existence of hypocalcemia and an exaggerated ACTH response should be observed carefully when managing pseudoaldosteronism.
Third Department of Internal Medicine, Hirosaki University School of Medicine, Aomori, Japan.
Kazunori
K
Kageyama
Shinobu
S
Takayasu
Takako
T
Moriyama
Satoru
S
Sakihara
Toshihiro
T
Suda
D000324:Adrenocorticotropic Hormone / Q000097:blood / Q000378:metabolism*; D000368:Aged; D001794:Blood Pressure; D002118:Calcium / Q000652:urine; D003346:Corticotropin-Releasing Hormone; D005260:Female; D019695:Glycyrrhizic Acid / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D006929:Hyperaldosteronism / Q000139:chemically induced / Q000150:complications* / Q000175:diagnosis / Q000378:metabolism*; D006996:Hypocalcemia / Q000150:complications*; D008107:Liver Diseases / Q000188:drug therapy; D011188:Potassium / Q000097:blood / Q000652:urine
D019695:Glycyrrhizic Acid; D000324:Adrenocorticotropic Hormone; D003346:Corticotropin-Releasing Hormone; D011188:Potassium; D002118:Calcium